Research Insights on 70 kDa Ribosomal Protein S6 Kinase - Pipeline Review, H2 2016

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) 
- The report reviews 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

ArQule, Inc. Astex Pharmaceuticals Inc Eddingpharm Merck KGaA PharmAust Limited Phoenix Biotechnology, Inc. Sentinel Oncology Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###